Dysport® 500U is a botulinum toxin type A product developed by Ipsen Biopharm Ltd. It is utilized for both therapeutic and aesthetic applications, functioning by inhibiting acetylcholine release at motor nerve endings to reduce muscle activity.
-
Rapid onset of action: Clinical improvements are typically observed within 2 to 3 days post-treatment.
-
Versatile applications: Effectively addresses various medical conditions, including cervical dystonia, blepharospasm, hemifacial spasm, and spasticity in both adults and children.
-
Proven efficacy: Extensive clinical experience spanning over 30 years, with marketing authorizations in more than 70 countries.
-
Therapeutic indications:
-
Treatment of focal spasticity in upper and lower limbs in adults.
-
Management of dynamic equinus foot deformity in ambulant pediatric cerebral palsy patients aged two years and older.
-
Alleviation of symptoms associated with cervical dystonia, blepharospasm, and hemifacial spasm.
-
-
Aesthetic indications:
-
Reduction of glabellar lines (frown lines) between the eyebrows.
-
The duration of effect varies depending on the indication and individual patient factors but generally ranges from 12 to 16 weeks.
Product composition: Each vial contains 500 units of Clostridium botulinum type A toxin-haemagglutinin complex, along with human albumin and lactose as excipients.
Packaging: Supplied as a lyophilized powder in single-dose vials containing 500 units each.
Manufacturer: Ipsen Biopharm Ltd., United Kingdom.
Dysport® 500U has specific contraindications and potential side effects. It is essential to consult with a qualified healthcare professional before undergoing treatment to determine its suitability for your condition. Self-administration is strongly discouraged.